Noxopharm (ASX:NOX) Change In Receivables : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Change In Receivables?

Noxopharm's change in receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil. It means Noxopharm's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Noxopharm's change in receivables for the fiscal year that ended in Jun. 2023 was A$0.00 Mil. It means Noxopharm's Accounts Receivable stayed the same from Jun. 2022 to Jun. 2023 .

Noxopharm's Accounts Receivable for the quarter that ended in Dec. 2023 was A$1.19 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Noxopharm's liquidation value for the six months ended in Dec. 2023 was A$5.47 Mil.

Noxopharm Change In Receivables Historical Data

The historical data trend for Noxopharm's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Change In Receivables Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Change In Receivables

Get a 7-Day Free Trial

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Change In Receivables	Get a 7-Day Free Trial											-	-	-	-	-

Noxopharm Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Noxopharm (ASX:NOX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Noxopharm's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.188	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Noxopharm's accounts receivable are only considered to be worth 75% of book value:

Noxopharm's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5.16	-	0.581	+	0.75 * 1.188	+	0.5 * 0
=	5.47

Noxopharm Change In Receivables Related Terms

Thank you for viewing the detailed overview of Noxopharm's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Noxopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines, based on two preclinical platforms. It is engaged in one segment which is the clinical development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm Headlines

No Headlines